Calidi Biotherapeutics
CLDI
23 hedge funds and large institutions have $39.6M invested in Calidi Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
79.06% more ownership
Funds ownership: 16.16% → 95.22% (+79%)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
17% more capital inflows, than outflows
Capital inflows: $15.2M | Capital outflows: $13M
15% more funds holding
Funds holding: 20 → 23 (+3)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$4.98M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$3.16M |
| 3 |
KL
KIM LLC
Wichita,
Kansas
|
+$2.55M |
| 4 |
Elequin Capital
New York
|
+$1.69M |
| 5 |
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$958K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Driehaus Capital Management
Chicago,
Illinois
|
-$9.31M |
| 2 |
LSC
Logan Stone Capital
Chicago,
Illinois
|
-$1.47M |
| 3 |
Cowen and Company
New York
|
-$893K |
| 4 |
Virtu Financial
New York
|
-$651K |
| 5 |
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$364K |
CLDI Hedge Fund Activity: Q4 2022 in Review
23 of the 6,241 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q4 2022, worth a combined $39.6M — up 9.7% from $36.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CLDI positions and 4 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $4.98M. The largest seller was Driehaus Capital Management, cutting an estimated $9.31M.
- 23 institutional investors held Calidi Biotherapeutics (CLDI) as of Q4 2022, up from 20 in Q3 2022.
- Funds reported $39.6M of Calidi Biotherapeutics stock for Q4 2022, up 9.7% quarter-over-quarter.
- 7 funds opened new Calidi Biotherapeutics positions in Q4 2022 and 4 closed out, a net change of +3 holders.
- The largest Calidi Biotherapeutics buyer in Q4 2022 was Hudson Bay Capital Management, an estimated $4.98M added.
- The largest Calidi Biotherapeutics seller in Q4 2022 was Driehaus Capital Management, an estimated $9.31M sold.
Based on aggregated 13F filings for Q4 2022.